E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
AtaiBeckley has become a wholly owned subsidiary of Eli Lilly and Company.
imphoenix82
Lilly aims to advance treatments for serious autoimmune and allergic diseases with the Merida acquisition. The transaction is expected to close in the fourth quarter of 2026.
imphoenix82
Lilly is calling on regulators, customs agencies, law enforcement authorities, online platforms, and payment companies to shut down the illegal retatrutide black market.
imphoenix82
Lilly is currently evaluating olomorasib in the Phase 1/2 LOXO-RAS-20001 trial involving patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) and other advanced solid tumours.
imphoenix82
Novo Nordisk alleges Lilly’s advertisements for Zepbound and Mounjaro mislead consumers by comparing the drugs with lower-dose versions of Wegovy and Ozempic.
imphoenix82
As part of Eli Lilly’s new national campaign, O’Neal is sharing his personal experience with moderate-to-severe obstructive sleep apnea, including his diagnosis and treatment journey with Zepbound (tirzepatide).
imphoenix82
In addition to weight loss, women taking Foundayo also experienced notable reductions in waist circumference, suggesting reduced abdominal fat and cardiometabolic risk, according to Eli Lilly.
imphoenix82
Lilly sees retatrutide as part of a broader portfolio approach to obesity care alongside its existing therapies Zepbound (tirzepatide) and Foundayo (orforglipron).
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
